Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Equity Income (2018 - 2025)

Historic Equity Income for Abvc Biopharma (ABVC) over the last 6 years, with Q3 2025 value amounting to -$54235.0.

  • Abvc Biopharma's Equity Income rose 2010.75% to -$54235.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$217914.0, marking a year-over-year increase of 3090.96%. This contributed to the annual value of -$221888.0 for FY2023, which is N/A changed from last year.
  • Abvc Biopharma's Equity Income amounted to -$54235.0 in Q3 2025, which was up 2010.75% from -$44917.0 recorded in Q2 2025.
  • Abvc Biopharma's 5-year Equity Income high stood at -$44917.0 for Q2 2025, and its period low was -$91765.0 during Q3 2021.
  • In the last 3 years, Abvc Biopharma's Equity Income had a median value of -$54235.0 in 2025 and averaged -$62979.4.
  • As far as peak fluctuations go, Abvc Biopharma's Equity Income skyrocketed by 8965.71% in 2021, and later skyrocketed by 2010.75% in 2025.
  • Quarter analysis of 3 years shows Abvc Biopharma's Equity Income stood at -$76697.0 in 2021, then increased by 11.49% to -$67885.0 in 2024, then rose by 20.11% to -$54235.0 in 2025.
  • Its Equity Income was -$54235.0 in Q3 2025, compared to -$44917.0 in Q2 2025 and -$50877.0 in Q1 2025.